Autel Energy Launches Next-Generation Charging Platform: From In-House Designed Liquid-Cooled Modules to Scalable Cabinet Systems, High-Performance Terminals, and Upgraded All-in-One Chargers
5.9.2025 09:30:00 CEST | Business Wire | Press Release
At its “INFINITE POWER – STARTING FROM ZERO” Global Launch Event, Autel Energy Europe introduced its most advanced EV charging platform to date, a next-generation solution designed to meet the surging demand for ultra-fast, reliable, and scalable charging infrastructure across Europe and beyond. Built on in-house engineered liquid-cooled power modules, the platform combines high performance with unmatched adaptability, providing operators flexible and scalable charging solutions that cover a vast majority of different use cases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250905051021/en/
Guests explore Autel’s latest charging solutions in the display area.
MaxiModule LCM60/120: High-Performance Liquid-Cooled Modules Developed In-House
At the core of the platform are Autel’s in-house developed MaxiModule LCM60/120 liquid-cooled power modules, available in 60 kW and 120 kW configurations. Engineered for high conversion efficiency, long-term stability, and sustained operation under demanding conditions, these modules deliver consistent thermal performance during continuous high-power use. For operators, the MaxiModule LCM60/120 offers not only technical robustness, but also tangible business value—lower total cost of ownership, higher uptime, and future-ready scalability.
MaxiCharger DS600L: Scalable Cabinet Systems with Redundant Architecture
The new power modules are integrated into Autel’s MaxiCharger DS600L cabinet system, engineered for scalability in large-scale charging infrastructure with a total output capacity of up to 3 MW per cabinet cluster.
To safeguard operational continuity, the MaxiCharger DS600L features a backup architecture for critical components such as power modules, control units and switching matrix — designed with the vision of achieving zero downtime. In combination with Autel’s terminal units, the system supports flexible site configurations with CCS and MCS compatibility, fleet and depot applications, and seamless integration of BESS and PV, all orchestrated through Autel’s EMS to optimize energy flow and operational efficiency. The DS600L can also be flexibly paired with a variety of dispensers and terminal units — from passenger car posts to heavy-duty truck dispensers — enabling tailored solutions for diverse site requirements. The MaxiCharger DT1500 terminal supports outputs of up to 1,500 A and 1.44 MW, ensuring readiness for next-generation ultra-fast charging demands.
All-in-One Charger Upgrade to MaxiCharger DH600
Autel has advanced its all-in-one charger line with the MaxiCharger DH600, an upgrade of the MaxiCharger DH480 that retains the series’ compact footprint and streamlined design while delivering significantly enhanced performance. The MaxiCharger DH600 is equipped with liquid-cooled charging cables supporting up to 650 A, enabling continuous high-power delivery of 600 kW with excellent thermal performance. With higher sustained performance, improved efficiency, and enhanced adaptability across diverse charging scenarios, the MaxiCharger DH600 guarantees reliable operation even under the most demanding conditions.
MaxiCare Service and AI Integration
In addition to hardware advancements, Autel highlighted MaxiCare service capabilities and AI-driven features. These tools support predictive maintenance, real-time network optimization, and improved user experience, enabling operators to manage infrastructure proactively, reduce downtime, and deliver a smoother charging process for drivers. Building on this, Autel is also exploring broader applications of AI in charging and inspection, further enhancing efficiency and laying the foundation for future innovations.
"By developing our core power modules in-house and integrating them into scalable cabinet systems, high-performance terminals, and next-generation all-in-one chargers, we are providing flexibility and reliability for the evolving EV charging market," said Andreas Lastei, Vice President of Sales and Marketing at Autel Europe. "Together with our intelligent service platform and AI capabilities —and full readiness for CCS, MCS, BESS, and PV— this launch provides a comprehensive foundation for building the charging networks of the future, supporting Europe’s transition to zero-emission transport.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250905051021/en/
Contacts
Jiaqi Liu
jiaqi.liu@autel.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom